Clinical Observation Of Middle And Advanced Cervical Cancer In Peishigongjingai Presction Combined With Synchtonous Radiotherapy And Chemothera

Objective:This study observed the combination of Peishigongjingai prescription and concurrent chemoradiotherapy in the treatment of middle and advanced cervical cancer,Peishigongjingai prescription of toxicity reduction and synergistic effect,the efficacy and safety of Peishigongjingai prescription for cervical cancer in the treatment of middle and advanced cervical cancer were discussed,and the mechanism of action was preliminarily studied.Method:Sixty patients were randomly divided into two groups,the treatment group and the control group were given Peishigongjingai prescription + concurrent chemoradiotherapy and concurrent chemoradiotherapy respectively.The clinical efficacy of Peishigongjingai prescription in the treatment of advanced cervical cancer was evaluated by recording the changes in SCC,TCM symptom score,and Karnofsky of each patient,as well as the changes in bone marrow suppression,skin,gastrointestinal and urinary tract reactions,and solid tumor size after concurrent chemoradiotherapy.At the same time,electrocardiogram,urine and fecal routine,liver and kidney function changes and adverse reactions were recorded during the study,so as to evaluate the safety and reliability of At the same time,electrocardiogram,urine and fecal routine,liver and kidney function changes and adverse reactions were recorded during the study,so as to evaluate the safety and reliability of Peishigongjingai prescription.Results:1.SCC: the SCC values of patients in both groups decreased after treatment,with an average value of 2.82±0.71,before treatment and 0.87±0.40.after treatment in the treatment group,2.80±0.77 before treatment and 1.86±0.73 after treatment in the control group.There was no significant difference between the two groups before treatment(P > 0.05).After treatment in comparison,the effect of medicines better(P<0.05).2.TCM clinical symptoms: both treatment methods can improve the symptoms of patients.The values of the treatment group and the control group before treatment were 14.55±2.88 and 13.72±2.83,respectively,and the difference was not statistically significant(P >0.05).After treatment,the clinical symptoms of both groups were improved,but the treatment group was superior to the control group(P<0.05).3.Karnofsky:Treatment of group averages 72.67 to 6.40 before treatment,after treatment79.33±5.21,before the control group therapy 73.33±6.61,76.00±5.63 is after treatment.Comparison of Two Groups,curative effect of treating groups in the area of the Karnofsky better(p<0.05).4.Side effects : Incidence of bone marrow inhibition control group,the treatment group were 76.67%,36.67%;treatment group,skin,digestive system and reacts to 10 cases of urinary,compared to 19 cases.The difference between the two groups showed that the Peishigongai prescription group had better efficacy in alleviating skin,gastrointestinal tract,urinary system reaction and bone marrow suppression than the simple concurrent chemoradiotherapy group,and the difference was statistically significant(P<0.05).5.Size of solid tumor: 25 cases of solid tumor were reduced in the treatment group,with a total effective rate of 83.33%,and 18 cases in the control group,with a total effective rate of60.00%.Both groups could reduce the size of solid tumor,but the effective rate was higher in the treatment group,and the difference was statistically significant(P<0.05).Conclution:Peishigongjingai prescription can reduce the value of SCC in patients with middle and advanced cervical cancer,improve the clinical symptoms of patients with traditional Chinese medicine,reduce bone marrow suppression,prevent adverse reactions of skin,gastrointestinal tract and urinary system,with good efficacy and safety.